由基因灭活百日咳毒素与丝状血凝素及百日咳杆菌黏附素组成的无细胞百日咳疫苗在婴幼儿中的免疫原性。
Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children.
作者信息
Podda A, Carapella De Luca E, Titone L, Casadei A M, Cascio A, Bartalini M, Volpini G, Peppoloni S, Marsili I, Nencioni L
机构信息
Biocine-Sclavo R&D Vaccines, Siena, Italy.
出版信息
J Pediatr. 1993 Jul;123(1):81-4. doi: 10.1016/s0022-3476(05)81543-4.
We studied the immunogenicity of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin (PT-9K/129G), filamentous haemagglutinin, and a 69-kilodalton protein, pertactin, in 30 children aged 12 to 24 months and in 80 infants aged 2 to 4 months. A significant increase of the neutralizing titer and of the titers against pertussis toxin, filamentous hemagglutinin, and pertactin, as determined by enzyme-linked immunosorbent assay, was achieved after three doses of vaccine in all the children; a significant increase of these antibody titers was obtained in 100%, 96.1%, 93.5%, and 98.7% of the infants, respectively.
我们在30名12至24个月大的儿童以及80名2至4个月大的婴儿中研究了一种无细胞百日咳疫苗的免疫原性，该疫苗由基因解毒的百日咳毒素（PT-9K/129G）、丝状血凝素和一种69千道尔顿的蛋白质——百日咳黏附素组成。通过酶联免疫吸附测定法测定，所有儿童在接种三剂疫苗后，中和效价以及针对百日咳毒素、丝状血凝素和百日咳黏附素的效价均显著提高；在婴儿中，这些抗体效价分别在100%、96.1%、93.5%和98.7%的婴儿中显著提高。
Zotero 插件